Butylone
Viewing r1 — May 3, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Butylone (bk-MBDB) is a synthetic stimulant-entactogen of the cathinone class. It is the β-keto structural analog of the entactogen MBDB, shorter-acting and less potent than MDMA. Butylone blocks dopamine reuptake while simultaneously triggering serotonin release,[1] producing a hybrid stimulant-entactogen effect.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
methylone, mephedrone, MDMA +2 moremethylone, mephedrone, MDMA, amphetamine, cocaine show less
First synthesized in 1967 as part of a β-keto phenethylamine series, butylone received no pharmacological study and remained obscure for nearly four decades. It surfaced on research chemical markets around 2005 and was swept into the global synthetic cathinone wave of 2009–2012, which prompted the first formal research. Butylone is now Schedule I in the United States[3] and controlled in most developed nations.
Subjective effects include euphoria, empathogenic warmth, increased energy, and prosocial behavior. The experience sits between stimulant push and entactogenic openness — social environments draw out warmth and connection, while solitary contexts emphasize wakefulness and drive. Anxiety, tachycardia, and residual stimulation are common unsought effects.
No dependence data exist, but moderate reinforcing potential is predicted from DAT activity.[4] Two fatalities are documented — one from combined serotonin syndrome,[5] one from intentional overdose at exceptionally high blood concentration.[6] No clinical trials have been conducted; the evidence base rests entirely on in vitro pharmacology, two fatality reports, and class-level animal data.
History[edit]
Discovery
Butylone was first synthesized in 1967 by Koeppe, Ludwig, and Zeile during systematic exploration of β-keto analogues of methylenedioxy phenethylamines.citation needed The compound — the β-keto version of Alexander Shulgin's entactogen MBDB — received no pharmacological characterization and remained an obscure chemical curiosity for nearly four decades.
Research chemical emergence and formal study
Butylone surfaced on research chemical markets around 2005, sold as bk-MBDB or as an unlabeled ingredient in "bath salt" mixtures. The global synthetic cathinone wave of 2009–2012 prompted the first formal pharmacological work: Baumann et al. characterized the broader methylenedioxy cathinone class,[7] and dedicated butylone studies by López-Arnau et al.[8] and Simmler et al.[2] followed the same year.
Fatalities and prohibition
Two deaths linked to butylone were reported in 2012: a combined methylone-butylone serotonin syndrome fatality[5] and an isolated butylone suicide in Poland.[6] Israel controlled butylone in 2009, the United Kingdom banned all cathinone derivatives in April 2010,[9] and the US DEA placed butylone in Schedule I temporarily in March 2014[10] and permanently in March 2017.[3]
The name bk-MBDB follows standard research chemical nomenclature: "bk" denotes the β-keto (cathinone) modification, and MBDB identifies the parent compound N-methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine. Butylone circulated during the peak "bath salts" era alongside Methylone, mephedrone, and MDPV, but was consistently described as the least distinctive member of the methylenedioxy cathinone series — less potent, less sought-after, and often present as an unlabeled adulterant rather than a product sold on its own merits.
Chemistry[edit]
Structural class
Butylone belongs to the synthetic cathinones — β-keto phenethylamines built on the cathinone scaffold. It carries a 3,4-methylenedioxy substitution on the phenyl ring, the same structural feature found in MDMA and MDA that confers serotonergic activity. The β-keto group (a carbonyl at the β-position) distinguishes cathinones from their amphetamine counterparts and generally reduces blood-brain barrier penetration, though butylone retains high permeability in vitro.[2]
Structurally, butylone is the β-keto structural analog of MBDB and a close homolog of methylone (bk-MDMA), differing from methylone by one additional carbon on the α-alkyl chain.
Molecular properties
| Molecular formula (free base) | C₁₂H₁₅NO₃ |
| Molecular weight (free base) | 221.25 g/mol |
| Melting point (HCl salt) | 223–228°C |
| LogP | 1.34 |
The molecule consists of a 1,3-benzodioxole ring connected to a 2-(methylamino)butan-1-one chain. Key functional groups include the methylenedioxy bridge, the β-carbonyl, and a secondary amine (N-methyl). The moderate LogP of 1.34 indicates balanced lipophilicity, consistent with the compound's confirmed ability to cross the blood-brain barrier.[11]
Stereochemistry
Butylone has one chirality center at carbon-2 of the butanone chain and is commercially distributed and studied exclusively as a racemic mixture. No enantioselective pharmacology studies have been published. For comparison, the related cathinone mephedrone shows significant differences in reinforcing properties between its enantiomers,[12] suggesting butylone's individual enantiomers may differ meaningfully — a gap that remains unaddressed.
Pharmacology[edit]
Mechanism of action
Butylone acts at all three monoamine transporters with a mechanistically split profile. At the dopamine transporter (DAT), it functions as a reuptake inhibitor — blocking dopamine clearance in a cocaine-like fashion rather than triggering dopamine release.[1][4]
At the serotonin transporter (SERT), it behaves as a substrate — entering the presynaptic terminal and triggering serotonin release through transporter reversal, mechanistically analogous to MDMA.[1][2]
At the norepinephrine transporter (NET), butylone acts as a reuptake inhibitor without robust norepinephrine release.[4]
This dual profile — DAT blocker and SERT releaser — underlies the hybrid stimulant-entactogen character. Dopamine reuptake inhibition drives energy and euphoria, while serotonin release produces empathogenic warmth and prosocial effects. Animal studies confirm that both serotonergic (5-HT₂A) and dopaminergic pathways contribute to butylone's behavioral effects, as demonstrated by dual blockade with ketanserin and haloperidol.[8]
Pharmacokinetics
No human pharmacokinetic studies have been published. Key parameters — half-life, bioavailability, peak plasma concentration, and volume of distribution — remain uncharacterized. Duration estimates of 3–5 hours oral derive from community reports and are unverified.safety citation needed
Urinary excretion studies indicate that methylenedioxy cathinones including butylone undergo less carbonyl reduction than non-methylenedioxy cathinones, and the parent compound is the most reliable detection target in urine.[13]
Liver metabolism involves CYP450 enzymes, though the specific isoforms responsible have not been identified.[14] A critical and counter-intuitive finding: CYP450 inhibitors increased butylone's toxicity to liver cells, indicating that metabolism generates toxic byproducts rather than detoxifying the parent compound. Standard assumptions about metabolic clearance providing safety do not apply.
Neuroscience[edit]
Where it acts
Butylone's DAT blockade increases dopamine levels in the mesolimbic mesolimbic pathway — the circuit running from the ventral tegmental area to the nucleus accumbens that underlies stimulant reward and motivation. Simultaneously, SERT-mediated serotonin release engages post-synaptic serotonin receptors broadly, including 5-HT₂A (confirmed behaviorally by ketanserin blockade of butylone-induced hyperlocomotion[8]) and 5-HT₁A pathways associated with anxiolytic and prosocial effects. No direct neuroimaging studies have been conducted with butylone.
Why it matters
Butylone's dual mechanism maps onto the "wanting" versus "liking" framework of reward: DAT blockade enhances incentive salience and approach motivation (wanting), while SERT-mediated serotonin release enhances hedonic impact and social reward (liking). This predicts moderate compulsive redosing drive moderated by serotonergic satiety — less compulsive than DAT-selective cathinones like MDPV.
In vitro studies show butylone produces dose-dependent neurotoxicity in human neuronal cells through oxidative stress, mitochondrial disruption, and programmed cell death,[15] though whether recreational doses achieve neurotoxic brain concentrations is unknown.
Key unknowns include whether butylone produces serotonin neurotoxicity (nerve terminal degeneration) in living organisms, as documented for MDMA. Whether its R- and S-enantiomers differ in reinforcing potential or toxicity has not been tested.
Subjective Effects[edit]
Butylone produces a hybrid experience sitting between stimulant drive and entactogenic openness. Social settings tend to foreground warmth, empathy, and prosocial connection, while solitary or task-focused contexts emphasize wakefulness and physical energy. The balance is unusually context-dependent — more so than either pure stimulants or dedicated entactogens.
Compared to MDMA, butylone is consistently described as less potent, shorter-acting, and shallower in entactogenic depth, with more prominent stimulation.[4] Relative to methylone, the experience is similar in character but lower in ceiling intensity, reflecting reduced affinity at all three monoamine transporters.
Effect Grid
At common doses, butylone's dual pharmacology becomes fully apparent. Stimulation is prominent — increased energy, thought acceleration, enhanced motivation — while entactogenic effects manifest as empathy enhancement, emotional warmth, music enhancement, and increased tactile pleasure. Social inhibitions decrease and conversation flows freely.
Physically, moderate tachycardia, pupil dilation, jaw clenching (bruxism), and diaphoresis are typical. Body temperature elevation occurs; dehydration risk increases with physical activity. Peripheral vasoconstriction may produce cool extremities.
Functional impairment is moderate. Sleep is impossible during effects and difficult for 1-2 hours afterward. Total commitment is approximately 4-6 hours including residual stimulation.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Synesthesia
Body high · Spontaneous body sensations · Dehydration sensation · Dry mouth · Insomnia · Pupil dilation · Excessive sweating · Bruxism · Heart rate perception changes · Muscle tension · Physical fatigue · Tactile euphoria · Tingling / electric sensations · Sexual arousal enhancement · Increased urination · Abnormal heartbeat · Headache · Nausea · Dizziness · Trembling · Vibrations / buzzing
Dry mouth · Insomnia · Pupil dilation · Excessive sweating · Bruxism · Heart rate perception changes · Muscle tension · Physical fatigue · Tactile euphoria · Tingling / electric sensations · Sexual arousal enhancement · Increased urination · Headache · Nausea · Dizziness · Trembling · Vibrations / buzzing
Openness enhancement · Motivation enhancement · Analysis enhancement · Motivation suppression · Focus enhancement · Information processing enhancement · Pattern recognition enhancement · Creativity enhancement · Humor enhancement · Language enhancement · Thought organization · Introspection enhancement · Thought deceleration
Focus enhancement · Information processing enhancement · Pattern recognition enhancement · Creativity enhancement · Humor enhancement · Language enhancement · Thought organization · Introspection enhancement · Thought deceleration
Irritability · Anhedonia · Anxiety · Dysphoria · Emotional lability
Emotional lability
Communication enhancement · Craving · Emotional susceptibility · Flow state · Ego inflation
Ego inflation
Timeline
First alerts manifest as subtle mood lift and mild physical restlessness. The wide onset range (15-60 minutes) reflects variability in gastric contents and individual metabolism.
Stimulation builds progressively — heart rate elevates, sociability increases, and the first hints of entactogenic warmth appear. Mild nausea may occur during this transition.
Maximum intensity of combined stimulant and entactogenic effects. Euphoria, empathy enhancement, music appreciation, and physical energy are at their strongest. Cardiovascular effects (tachycardia, mild hypertension) are most pronounced.
Effects plateau at reduced intensity — stimulation persists while entactogenic warmth gradually fades. Redosing urge may emerge as serotonergic satiety diminishes but dopaminergic drive remains.
Gradual return to baseline. Residual stimulation outlasts the empathogenic effects. Mild fatigue, irritability, or low mood may begin as monoamine stores deplete.
Residual effects include low-grade fatigue, mildly depressed mood, and possible difficulty sleeping due to lingering noradrenergic stimulation. Cognitive function is subtly impaired.
⚠ Do not drive or operate machinery until after a full night's sleep following butylone use.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- methylone · mephedrone · MDMA
Toxicity
No lethal dose has been established for butylone in any species. No therapeutic index can be calculated.
Acute toxicity
Two human fatalities are documented. The first involved combined methylone and butylone ingestion sold as "Ecstasy," resulting in fatal serotonin syndrome with death at 48 hours.[5] The second was an isolated butylone suicide in Poland with a postmortem blood concentration of 20 mg/L[6] — an exceptionally high level, as most cathinone-related fatalities involve blood concentrations below 1 mg/L.[16]
Blood concentration does not reliably predict outcome for cathinones.[17][18] Class-level acute toxicity includes rapid heart rate, high blood pressure, dangerous overheating, and in severe cases muscle breakdown, metabolic acidosis, and organ failure.[19][20][21]
Liver toxicity
In vitro studies show butylone damages liver cells through oxidative stress, mitochondrial disruption, and programmed cell death.[14] CYP450 inhibitors increased cellular toxicity rather than reducing it — meaning the liver's metabolic processing of butylone generates toxic byproducts rather than clearing the drug safely. Metabolic "clearance" does not equal detoxification for this compound.
Neurotoxicity
Butylone causes dose-dependent cell death in human neuronal cell cultures through reactive oxygen species production, mitochondrial damage, calcium dysregulation, and programmed cell death.[15] No in vivo neurotoxicity studies have been conducted, so whether recreational doses achieve neurotoxic concentrations in the brain is unknown.
Psychological risks
No controlled data on psychological adverse effects specific to butylone exist. Class-level cathinone surveys report anxiety, paranoia, agitation, and psychosis as adverse effects.[22] The serotonin syndrome case included coma and severe agitation prior to cardiovascular collapse.[5]
Given butylone's serotonergic activity, serotonin-mediated psychiatric emergencies — agitation, confusion, dangerous overheating — represent the primary acute psychological risk. Whether butylone can trigger persistent psychotic disorders, as documented for high-potency DAT-selective cathinones like MDPV, is unknown but considered less likely given its lower DAT potency.
Tolerance and dependence
No human tolerance or dependence studies exist for butylone. Class-level animal evidence shows cathinones with dopamine transporter activity support self-administration, with reinforcing potential proportional to DAT potency.[23][12]
Butylone's moderate DAT blocking activity predicts moderate reinforcing potential — less compulsive than MDPV or mephedrone, but greater than compounds without DAT activity. Concurrent serotonergic activity may provide a degree of self-limiting character (serotonin-mediated satiety) similar to that observed with MDMA versus pure stimulants.
Community-reported tolerance timelines (full reset ~1.5 weeks) are unverified against published pharmacological data.safety citation needed Cross-tolerance with other dopaminergic stimulants is pharmacologically predicted but not experimentally confirmed.
Drug interactions
The primary interaction risk is additive serotonin toxicity. Butylone releases serotonin via SERT; co-administration with any serotonergic agent compounds the risk.
The Warrick case directly documents fatal serotonin syndrome from combined methylone and butylone ingestion (~844 mg methylone + ~106 mg butylone).[5]
High-risk serotonergic combinations include:
- MAOIs (phenelzine, tranylcypromine, moclobemide): prevent serotonin degradation; combination with any serotonin releaser is potentially lethal
- SSRIs/SNRIs (fluoxetine, sertraline, venlafaxine): additive serotonin effects; SSRIs that inhibit CYP450 may also alter butylone metabolism unpredictably
- Tramadol: serotonin reuptake inhibitor plus opioid activity creates clear serotonin syndrome risksafety citation needed
- Other MDMA analogues and cathinones: additive serotonergic load, as demonstrated in the Warrick case
CYP450 inhibitors increase butylone liver toxicity in vitro,[14] meaning polydrug combinations involving CYP inhibitors produce unpredictable effects — potentially reducing toxic metabolites while increasing parent compound exposure in the brain.
Combination with other stimulants (amphetamines, cocaine, cathinones) produces additive cardiovascular stress: elevated blood pressure, rapid heart rate, and dangerous overheating scale with total stimulant load.
Contraindications
No butylone-specific contraindication data exist in published literature. The following are inferred from its pharmacological mechanism:
- Heart conditions: stimulant effects (rapid heart rate, elevated blood pressure) pose direct risk to individuals with pre-existing cardiac disease or structural heart abnormalities
- Liver impairment: CYP450-dependent metabolism generates toxic byproducts; compromised liver function may alter the balance of parent compound versus toxic metabolite exposure
- Concurrent serotonergic medication: absolute contraindication given documented lethal serotonin syndrome
- Psychiatric conditions: monoamine stimulation may trigger mania, psychosis, or severe anxiety in predisposed individuals
- Pregnancy: no reproductive data exist; stimulant and serotonergic effects pose theoretical fetal risk
- Seizure disorders: cathinones lower seizure threshold via monoaminergic mechanisms
Harm Reduction[edit]
Forms & Identification
Butylone typically appears as a white to off-white crystalline powder, visually indistinguishable from methylone, ethylone, or other cathinones. Because it circulated heavily during the "bath salts" era — frequently as an unlabeled component — reagent testing alone cannot reliably distinguish it from closely related cathinones. Quantitative analysis or drug checking services provide the strongest identification confidence and are strongly recommended before any use.
Guidelines
- Test every batch with reagent kits and, where available, quantitative drug checking services
- Start with a low dose and wait at least 90 minutes before considering redosing — onset timing varies and stacking doses is the most common path to adverse effects
- Eat a light meal 2–3 hours before; avoid dosing on a full or empty stomach
- Stay hydrated with moderate water intake (roughly 250 mL per hour of activity)
- Have a sober companion present, especially for first experiences
- Set a hard redosing limit before the session begins — DAT activity creates a redosing urge that feels more reasonable than it is
- Avoid use on consecutive days; allow at least two weeks between sessions
Set & Setting
Social environments draw out butylone's entactogenic qualities, while solitary settings emphasize stimulant drive. Choose the context deliberately. A familiar, comfortable environment with trusted people reduces anxiety risk. Avoid physically demanding settings (extended dancing, hot venues) where stimulant-driven overheating becomes dangerous. Have water accessible but avoid over-hydration — a class-level risk with serotonin-releasing compounds.
Aftercare & integration. The stimulant comedown from butylone may include low mood, fatigue, irritability, and difficulty sleeping. Prioritize sleep recovery — a quiet, dark environment and screen avoidance help. Eat nutritious food even if appetite is suppressed; light meals with protein and complex carbohydrates support neurotransmitter replenishment.
If the experience involved strong emotional content (common with serotonin-releasing compounds), allow time to process. Journaling or conversation with a trusted person within 24–48 hours helps consolidate insights and identify lingering distress. Persistent low mood, anxiety, or sleep disruption lasting more than a week warrants professional support.
Recovery & Support
Butylone's moderate reinforcing potential means compulsive use patterns are possible, particularly with frequent redosing. If use has become habitual or difficult to control, structured support is available. SAMHSA's National Helpline (1-800-662-4357) provides free, confidential referrals. Online communities such as r/StopSpeeding and SMART Recovery offer peer support specifically relevant to stimulant and cathinone use patterns.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Uncomfortable stimulation (jaw tension, restlessness, mild anxiety) is unpleasant but not dangerous. Seek immediate help for: chest pain or pressure, seizure, loss of consciousness, body temperature hot to the touch through clothing, severe confusion or agitation that cannot be talked down, or blue-grey skin color.
Immediate steps:
- 1. Move the person to a cool, quiet area
- 2. Call emergency services if any red-flag symptoms are present
- 3. If unconscious but breathing, place in the recovery position (on their side, airway clear)
- 4. Cool actively: remove excess clothing, apply cool water to neck, armpits, and groin
- 5. Do NOT induce vomiting; do NOT restrain unless there is immediate danger of self-harm
What to tell the dispatcher: Name the substance (butylone / synthetic cathinone), approximate amount and time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from prosecution — calling for help is always the right decision.
Legal Status[edit]
Butylone is controlled in most developed nations, classified alongside other synthetic cathinones under scheduling frameworks enacted between 2009 and 2017. Israel was the first jurisdiction to specifically control the compound (2009), and the United States was among the last major nations to permanently schedule it (2017). In jurisdictions without specific listing, structural analog legislation or generic cathinone definitions typically apply.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Temporary Schedule I effective March 7, 2014; permanent March 1, 2017. DEA code 7541.[24][3] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Effective April 16, 2010 via generic cathinone amendment (S.I. 2010/1207).[9] |
| China | Category I psychotropic substance | Effective September 2010.[9] |
| Israel | Controlled substance | Effective 2009 — earliest known national control.[9] |
| Japan | Designated Substance (Shitei Yakubutsu) | Controlled under designer drug legislation.[9] |
| Norway | Controlled (analog legislation) | Under Derivatbestemmelsen (derivative provisions).[9] |
| Slovakia | Controlled substance | Effective March 1, 2011.[9] |
| Finland | Controlled substance | Effective December 2014.[9] |
| Italy | Table I controlled substance | Listed in national controlled substances table.[9] |
Analog provisions
Prior to explicit scheduling in the United States (March 2014), butylone was subject to the Federal Analogue Act (21 U.S.C. § 813) as a structural analogue of scheduled cathinones intended for human consumption. Several US states enacted controls earlier: Virginia placed butylone in Schedule I effective July 1, 2012; Kentucky and Vermont controlled it in 2012 via state legislation.[9]
No EU-wide scheduling decision specific to butylone was identified. The compound falls under national cathinone controls in individual EU member states. Canada and Australia specific classifications were not confirmed — butylone likely falls under analog provisions in both jurisdictions.
references
- [1] ^abcSaha K, Li Y, Holy M, Lehner KR, Bukhari MO, Partilla JS, Sandtner W, Sitte HH, Baumann MH (2019) The synthetic cathinones, butylone and pentylone, are stimulants that act as dopamine transporter blockers but 5-HT transporter substrates. — Psychopharmacology doi:10.1007/s00213-018-5075-5
- [2] ^abcdSimmler LD, Buser TA, Donzelli M, et al. (2012) Pharmacological characterization of designer cathinones in vitro — British Journal of Pharmacology doi:10.1111/j.1476-5381.2012.02145.x
- [3]
- [4] ^abcdEshleman AJ, Wolfrum KM, Hatfield MG, Johnson RA, Murphy KV, Janowsky A (2013) Substituted methcathinones differ in transporter and receptor interactions — Biochemical Pharmacology doi:10.1016/j.bcp.2013.04.004
- [5]
- [6] ^abcRojek S, Kłys M, Strona M, Maciów M, Kula K (2012) Legal highs--toxicity in the clinical and medico-legal aspect as exemplified by suicide with bk-MBDB administration. — Forensic Science International doi:10.1016/j.forsciint.2012.04.034